U.S. drug pricing is set to enter a more tightly linked and closely monitored phase in 2026 as overlapping policy timelines across Medicare, Medicaid, and the 340B program begin to take effect together, according to Simon-Kucher. While pricing across these programs has
As Simon-Kucher notes, “that era is over,” driven less by any single rule change than by synchronized implementation and stronger enforcement tools that make it easier to see how concessions, unit definitions, and channel strategies interact in practice.
The result is a system that is more coupled, transparent, and sensitive to design choices. Decisions around where discounts sit, how rebates are structured, and how services are classified now carry greater risk of spillover into Best Price, Average Sales Price, and downstream reimbursement.
New requirements—such as excluding 340B units from Part D inflation rebates beginning in 2026—push the system toward unit-level traceability, while CMS data collection on acquisition costs turns pricing spreads into measurable inputs for future payment models. Proposed MFN-style benchmarks and next-generation Medicare models further anchor net-price expectations. Together, these shifts mark what Simon-Kucher describes as a system that is “more tightly coupled and more observable,” raising the stakes for launch, lifecycle, and gross-to-net planning decisions.